GLP-1 Studio
GLP-1 Studio Daily
What did stopping GLP-1s do to heart risk?
0:00
-3:56

What did stopping GLP-1s do to heart risk?

Plus pregnancy guidance, an oral GLP-1 and collagen demand
A black stethoscope lying on a light blue background
Photo by Etatics Inc. on Pexels

Good morning! Stopping GLP-1s was linked to more heart attacks and strokes in people with type 2 diabetes. Also today: new GLP-1 pregnancy guidance from the American College of Obstetricians and Gynecologists, first human results coming for Biomea Fusion's GLP-1 taken by mouth, and a human collagen program pointing to GLP-1 weight loss. Listen to me read them above, or read the key details below.

Daily Roundup:

  1. Stopping GLP-1s was linked to more heart attacks and strokes in people with type 2 diabetes (Devon Live)

  2. The American College of Obstetricians and Gynecologists now advises stopping GLP-1s before pregnancy (NPR Short Wave)

  3. Biomea Fusion will present early results for BMF-650, a GLP-1 drug taken by mouth (Biomea Fusion)

  4. Conexeu Sciences started a human collagen program for aesthetics, pointing to demand after GLP-1 weight loss (Conexeu Sciences)


Stopping GLP-1s was linked to more heart attacks and strokes in people with type 2 diabetes

Key Details:

  • Researchers in Italy and at Guy's and St Thomas' NHS Foundation Trust in London used records from more than 300 Italian diabetes clinics, covering more than 80,000 people with type 2 diabetes on GLP-1 drugs.

  • The risk of a non-fatal heart attack, a non-fatal stroke or death from any cause was about twice as high for those who came off the drugs. The team said that is about four cases per 100 people a year, compared with two per 100 among those who kept taking them.

  • People who continued were on the drugs for nearly three years on average, and those who quit for just over one year.

  • Writing in the journal Lancet Regional Health Europe, the researchers stressed the study was observational, so the people who stopped may already have been in poorer health, and it did not look at why they stopped. Dr Faye Riley of Diabetes UK said "Anyone with type 2 diabetes who is considering stopping treatment should speak to their healthcare team first."

Source: Devon Live


The American College of Obstetricians and Gynecologists now advises stopping GLP-1s before pregnancy

Key Details:

  • The group released the guidance in October to help OB/GYNs counsel their patients about these drugs and pregnancy.

  • Amy Valent, an OB/GYN at Oregon Health and Science University who worked on the guidance, said that means one or two months ahead, depending on how long each drug stays in the body.

  • She said tirzepatide, sold as Mounjaro and Zepbound, has been shown to lower some of how well birth control pills work. Her advice is a backup barrier method for a month when starting or changing the dose, or a method that is not a pill, like an IUD or an arm implant.

  • Questions about GLP-1s, fertility and pregnancy come up often in her clinic. "It probably comes up every other patient."

Source: NPR Short Wave


Biomea Fusion will present early results for BMF-650, a GLP-1 drug taken by mouth

Key Details:

  • The phase 1 results come from the drug's first study in people. They will be shown as a poster at the ObesityWeek 2026 conference in National Harbor, Maryland, on Monday, November 16.

  • The announcement does not share any of the results. The company says the poster will go on its website after the conference ends.

  • BMF-650 is investigational, which means it is not approved.

Source: Biomea Fusion press release (The Manila Times)


Conexeu Sciences started a human collagen program for aesthetics, pointing to demand after GLP-1 weight loss

Key Details:

  • Its first step was a pilot batch of human type one collagen. The company says it met its own specifications in internal testing that has not been independently checked or peer reviewed.

  • The collagen is for CXU, an injectable the company is developing. It goes in as a liquid, sets into a gel at body temperature, and becomes a temporary scaffold the body remodels into its own tissue.

  • None of this is approved, and its 12-month study was in animals. The company plans to submit its lead device, Ten Minute Tissue, to the FDA in early 2027 with wound care as its first use, and any product made with human collagen would need a separate review.

  • Chief executive Miles Harrison said "GLP-1 has created a new patient profile: people whose bodies have changed faster than today's aesthetic injectables were built to address, and restoring that tissue takes more than volume."

Source: Conexeu Sciences press release (The Manila Times)


Learn More

Amanda Bonello

This is a reader-supported publication, thank you so much for your support.

💖

Instagram · TikTok · LinkedIn


Disclaimer: I was not paid, sponsored, or compensated in any way for this episode or article. Nothing in this article, podcast, or platform should be used as a substitute for professional medical care, diagnosis, or treatment. Always consult with a qualified healthcare provider about your health decisions. I also do not formally endorse any news source, clinic, or company featured.

Discussion about this episode

User's avatar

Ready for more?